Literature DB >> 25729274

Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.

Junesun Kim1, Youngkyung Kim2, Suk-Chan Hahm1, Young Wook Yoon2.   

Abstract

Cholecystokinin is known to be involved in the modulation of nociception and to reduce the efficacy of morphine analgesia. This study investigated the effects of intrathecal administration of morphine and the cholecystokinin type B antagonist CI-988 on below-level neuropathic pain after spinal cord injury in rats. We also examined the interaction of morphine and CI-988 in the antinociceptive effect. Both morphine and CI-988 given individually increased the paw withdrawal threshold to mechanical stimulation in a dose-dependent manner. The combination of ineffective doses of intrathecally administered CI-988 and morphine produced significant analgesic effects and the combination of effective doses resulted in analgesic effects that were greater than the sum of the individual effects of each drug. Thus, morphine showed a synergistic interaction with CI-988 for analgesia of central neuropathic pain.

Entities:  

Keywords:  Cholecystokinin; Morphine; Neuropathic pain; Spinal cord injury; Synergistic interaction

Year:  2015        PMID: 25729274      PMCID: PMC4342732          DOI: 10.4196/kjpp.2015.19.2.125

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  33 in total

1.  Efficient analysis of experimental observations.

Authors:  W J Dixon
Journal:  Annu Rev Pharmacol Toxicol       Date:  1980       Impact factor: 13.820

2.  In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.

Authors:  J J Idänpään-Heikkilä; S Perrot; G Guilbaud; V Kayser
Journal:  Eur J Pharmacol       Date:  1997-05-01       Impact factor: 4.432

Review 3.  Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion.

Authors:  Andrea L O Hebb; Jean-François Poulin; Sean P Roach; Robert M Zacharko; Guy Drolet
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-10-20       Impact factor: 5.067

Review 4.  Opioid-modulating peptides: mechanisms of action.

Authors:  Catherine Mollereau; Michel Roumy; Jean-Marie Zajac
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

5.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

6.  Cortical changes in cholecystokinin mRNA are related to spontaneous pain behaviors following excitotoxic spinal cord injury in the rat.

Authors:  Kori L Brewer; David McMillan; Todd Nolan; Kerry Shum
Journal:  Brain Res Mol Brain Res       Date:  2003-10-21

7.  Cholecystokinin in mammalian primary sensory neurons and spinal cord: in situ hybridization studies in rat and monkey.

Authors:  V M Verge; Z Wiesenfeld-Hallin; T Hökfelt
Journal:  Eur J Neurosci       Date:  1993-03-01       Impact factor: 3.386

Review 8.  Mechanisms of chronic central neuropathic pain after spinal cord injury.

Authors:  Claire E Hulsebosch; Bryan C Hains; Eric D Crown; Susan M Carlton
Journal:  Brain Res Rev       Date:  2008-12-25

9.  Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat.

Authors:  X J Xu; M J Puke; V M Verge; Z Wiesenfeld-Hallin; J Hughes; T Hökfelt
Journal:  Neurosci Lett       Date:  1993-04-02       Impact factor: 3.046

Review 10.  Opioid and anti-opioid peptides.

Authors:  F Cesselin
Journal:  Fundam Clin Pharmacol       Date:  1995       Impact factor: 2.748

View more
  1 in total

Review 1.  Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges.

Authors:  Joanna Starnowska-Sokół; Barbara Przewłocka
Journal:  Molecules       Date:  2020-11-25       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.